Currenc Group Inc

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Currenc Group, Inc. engages in operating a fintech banking platform. It operates through the following segments: Remittance Services, Sales of Airtime, and Other Services. The company is headquartered in Singapore.

Pharmaceutical company CURE Pharmaceutical Holding Corp. (OTC:CURR) announced earnings results on Tuesday for the quarter ended June 30, revealing revenue of $2.1 million. That's a year-over-year increase of 700%.

CURE Pharmaceutical Q2 2021 Revenue Spikes 700% After Increased Sales From Seba Labs Products Including A CVS Deal

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced results for the quarter ended June 30, 2021, including the following highlights: Revenue of $2.1 million reflected an increase of nearly 700% from a year ago Gross profit rose 676% to $1.31 million compared to 2Q 2020 Net loss from operations of $3.27 million improved substantially compared to a net loss from operations of $13.47 million a year ago Operational Highlights Key operational highlights du

CURE Pharmaceutical Reports Second Quarter 2021 Revenue Rose Nearly 700% Driven by Sales from Sera Labs Product Lines

LOS ANGELES--(BUSINESS WIRE)--Sera Labs, a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced that all six facial products of the Seratopical Revolution skincare line will be available for purchase at CVS in the Fall of 2021. CVS is one of the leading national drug store chains in America. Seratopical Revolution marries nature and science into one clean and nourishing line of beauty products. The line's P3P complex, developed by CURE Pharmaceutical, drives natural, cle

Seratopical Revolution Skincare Line by The Sera Labs Inc., a CURE Pharmaceutical Company, will be Available for Purchase this Fall at CVS, one of the Leading National Drug Store Chains

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness markets, announced today that its Chief Business Officer Jonathan Berlent will participate in a virtual presentation at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on Thursday, June 17. "The potential therapeutic benefits of psychedelics to treat m

CURE Pharmaceutical to Present at H.C. Wainwright 2021 Psychedelics in Psychiatry and Beyond Virtual Conference

CURE Pharmaceutical (OTC:CURR) has signed an agreement with Biopharmaceutical Research Company (BRC) to produce federally compliant medical cannabis, CBD and THC products. BRC will provide the cannabinoid ingredients and CURE will use them to begin the development of CBD and THC oral thin films for CURE's clinical studies targeted at advancing veteran health.

Federally Compliant Medical Cannabis In The US? One Company Is Doing It

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has signed a partnership agreement with Biopharmaceutical Research Company, (BRC), an active Drug Enforcement Administration (DEA) license holder, to produce federally-compliant cannabis-based medical products. Currently, CURE uses its Schedule 1 DEA license for the development of Cannabis (THC) oral film products and othe

CURE Pharmaceutical Signs Agreement to Develop CBD and THC Oral Thin Films and Conduct Clinical Studies Targeting Veteran Health

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, today announced that it will hold a webcast with the investment community on Thursday, May 27, at 5 p.m. Eastern Daylight Time. Rob Davidson, CEO of CURE Pharmaceutical Holding (OTCQB: CURR), Nancy Duitch, CEO of wholly-owned subsidiary The Sera Labs and Chief Strategy Officer for the Company, and management from both the pharmaceutical and welln

CURE Pharmaceutical Schedules Investor Webcast for Thursday, May 27, 2021

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, reported its financial results and provided an operational update for the first quarter ended March 31, 2021. First Quarter 2021 and subsequent weeks highlights: Total revenue rose more than 400% to $1.5 million compared with a year ago and gross profit rose in line with revenue growth. Received approval for an Investigational New Drug (IND) appl

CURE Pharmaceutical First Quarter Revenue Quadruples to $1.5 million; Company Expands Clinical Pipeline to Include Psychedelics

LOS ANGELES--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has secured International Organization for Standardization (ISO) 9001 certification for its Oxnard, Calif., manufacturing and research facility. ISO 9001 certification recognizes excellence in quality management standards of an organization that places an emphasis on its customers, the motivation and

CURE Pharmaceutical Receives ISO Certification for Laboratory and Manufacturing Facility

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that Rob Davidson, CURE's Chief Executive Officer, and Nancy Duitch, CEO of subsidiary Sera Labs and Chief Strategic Officer of CURE, will be presenting virtually at a cannabis investing conference, the 2021 Sequire Cannabis Conference, on Tuesday, April 20, at 2 p.m. EDT/11 a.m. PDT. Davidson and Duitch will discuss a variety of

CURE Pharmaceutical to Present at the 2021 Sequire Cannabis Conference on Tuesday, April 20, at 2 p.m. EDT/11 a.m.

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, reported its financial and operating results for the year ended Dec. 31, 2020, and provided recent operational highlights. The Company's total revenue of $2.1 million rose 229% compared to fiscal year 2019. On a pro forma basis, which includes full year revenue generated from CURE's wholly owned subsidiary The Sera Labs, Inc., acquired October 2,

CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has secured an extension to its Schedule I U.S. Drug Enforcement Agency (DEA) license that will allow the Company to conduct research on psychedelics-based pharmaceuticals using compounds such as LSD, MDMA, and psilocybin as potential treatments for various mental health disorders. The license ena

CURE Pharmaceutical Augments Its Existing U.S. DEA License in Order to Initiate Development of Its Psychedelics-Based Pharmaceutical Clinical Pipeline

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has launched a new initiative for the clinical development of psychedelic compounds such as psilocybin, LSD, and MDMA for the treatment of various mental health disorders. Utilizing CURE's patented oral film platform CUREfilm® for precision dosing, the company intends to optimize the absorption an

CURE Pharmaceutical Launches Psychedelic Oral Film Program Targeting the Treatment of Mental Health Disorders

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has launched two new clinical development programs and added new corresponding products to its growing pharmaceutical pipeline. The first is an antiviral clinical development program where the Company will look to load a known active pharmaceutical ingredient (API) onto its patented drug delivery

CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications

LOS ANGELES & OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space today announced that its subsidiary Sera Labs has launched a robust national advertising campaign for its Nutri-Strips thin-film product Sleep A.S.A.P.™ which offers a solution to America's sleep problem. The global market for sleep ai

CURE Pharmaceutical's Subsidiary Sera Labs Launches National Television, Radio & Digital Advertising Campaign for Nutri-Strips Sleep A.S.A.P.

OXNARD, Calif.--(BUSINESS WIRE)---- $CURR #CBD--CURE Pharmaceutical Holdings (“CURE” or the “Company”) (OTC: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness products and drug delivery, announced today updates and additions to its Board of Directors. After a dedicated run as Chairman of the Board, William Yuan is stepping down and will continue to serve the Company as an advisor and Chairman Emeritus. Rubén José King-Shaw Jr, a highly qualified and respected member of

CURE Pharmaceutical Announces Promotions and Additions to Board of Directors

LOS ANGELES & OXNARD, Calif.--(BUSINESS WIRE)---- $CURR #CBD--According to the National Institute of Health (NIH) more than 50 percent of people worldwide have Vitamin D insufficiency. In response, Sera Labs, Inc., a wholly owned subsidiary of CURE Pharmaceutical Holdings (OTCQB: CURR), announced today that it is unveiling “ImmunD₃,” a convenient, science-backed oral thin-film that provides a weekly dose of Vitamin D (40,000 IU) as a part of its Nutri-Strips™ line of novel and innovative vitamins and suppleme

Sera Labs Unveils ImmunD₃™ an Important New Offering to the Nutri-Strips™ Product Line; Launches New Digital E-commerce Website to Amplify Consumer Awareness

LOS ANGELES & OXNARD, Calif.--(BUSINESS WIRE)---- $CURR #CBD--The retailers have spoken! Sera Labs, Inc., the wholly owned subsidiary of CURE Pharmaceutical Holdings (OTCQB: CURR), announced today they have won the coveted Retail Excellence (REX Award) for Natural Products. The Rex Awards have a long history of recognizing, and honoring category leaders in the industry. Sera Labs, the premiere health, wellness and anti-aging CBD and plant-based skincare company beat out hundreds of nominees for this highly so

Sera Labs, Inc. Wins Prestigious Retail Excellence Award

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology-focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced today that the Company's Chief Executive Officer Rob Davidson will be presenting virtually at NobleCon17, Noble Capital Markets' Seventeenth Annual Institutional Investor Conference, on Tuesday, January 19, at 3:00 p.m. EST. Davidson will discuss how CURE continue

CURE Pharmaceutical to Present at 2021 NobleCon17 on Tuesday, January 19 at 3pm EST/12pm PST

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp (“CURE” or the “Company”) (OTC: CURR), a technology-focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced today that the Company's Chief Executive Officer Rob Davidson will be presenting at the H.C. Wainwright BioConnect 2021 Virtual Conference being held January 11-14. The presentation can be viewed beginning at 6:00 a.m. EST on January 11, 2

CURE Pharmaceutical to Present at H.C. Wainwright BioConnect 2021 Virtual Conference

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holdings (“CURE” or the “Company”) (OTCQB: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness products and drug delivery, today announced that management will present on the company at the LD Micro Main Event Conference on Tuesday, December 15, 2020 at 11:00 AM Pacific Time. Additionally, the Company will host a video webcast with the investment community on Thursday, December 17, 2020, at 4:00 p.m. East

CURE Pharmaceutical to Present at LD Micro on December 15, Schedules Investor Video Webcast for December 17

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holdings (“CURE” or the “Company”) (OTC: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness products and drug delivery, announced today that it has issued a letter to its shareholders providing commentary on the Company's recent announcements and upcoming plans. Highlights of the letter include: The Company's efforts to further position itself as an integrated healthcare company with its recent acquisiti

CURE Pharmaceutical Issues Letter to Shareholders

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Closes $10 Million Financing

CURE Pharmaceutical Closes $10 Million Financing

LOS ANGELES & OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding (OTCQB: CURR) wholly owned subsidiary Sera Labs is challenging the status quo of the health and wellness sector by bringing innovative products to market using groundbreaking technology and superior ingredients. As a trusted industry leader that continues to offer consumer solutions, Sera Lab's is launching the Nutri-Strips brand with a multi-channel advertising and marketing strategy beginning initially with “Sleep A.S.

CURE Pharmaceutical's® Wholly Owned Subsidiary SeraLabs® Introduces Nutri-Strips™, a Revolutionary Oral Thin Film Strip Technology

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holdings (OTC: CURR) today announced its definitive agreement to acquire Sera Labs, Inc. The closing is anticipated to occur in early October.

CURE Pharmaceutical Completes $20 Million Acquisition of Sera Labs, a Leading Health, Wellness and Beauty Brand Marketing and Multi-Channel Distribution Platform Company

News for Currenc Group Inc Stock (CURR)